Breast cancer cells, including triple negative breast cancer, upon pharmacological IRE1 inhibition, display reduced expression of immune modulators such as interleukin 8 (IL-8), C-X-C Motif Chemokine Ligand 1 (CXCL1), or transforming growth factor-beta 2 (TGF2) (Logue et al. 2018). This evidence concerns the gene ERN1 and triple-negative breast carcinoma.